Inspiration Healthcare Reports 41% Revenue Growth and Record H1 Performance

The Group also guides to a “further improvement in net debt” in H2, which, if delivered, would represent a second consecutive half of balance sheet progress. Net debt is simply borrowings minus cash – lower is better for financial flexibility.

Outlook: momentum into H2 and confidence in full-year delivery

The pipeline is described as strong, with momentum continuing into H2 FY26. The Company remains confident in meeting full-year expectations, although no numeric guidance is provided in this update. “Ahead of market expectations” on revenue for the half will be taken positively by investors, especially alongside margin recovery and debt reduction.

We’ll get the fuller picture – profit lines, cash flow detail and margin percentages – with interim results on Tuesday, 7 October 2025. Analyst and investor meetings will follow.

Key numbers at a glance

Metric	H1 FY26 (to 31 July 2025)	Comment
Revenue	£24.0 million	Record half-year; ahead of market expectations
Revenue growth	41%	H1 FY25: £17.0 million
Gross margin	Improved	Exact percentage not disclosed
Net debt	£6.7 million	Down £1.6 million vs £8.3 million at 31 January 2025
Humanitarian contract	$6 million	Fully delivered; majority paid; remainder due early H2 on installation
Middle Eastern contract	Not disclosed	First shipment delivered and paid; balance expected H2 pending letter of credit
EBITDA	Improved	Exact figure not disclosed
Interim results date	7 October 2025	Analyst and investor meetings to follow

Why this matters for investors

• Turnaround traction: The “back-to-basics” approach is translating into revenue growth, margin recovery and lower net debt. That is the right sequence for a sustainable recovery.
• Mix shift tailwind: Strong sales of higher margin capital items lift gross margin. If that mix persists, profitability should continue to improve.
• Order conversion to cash: The $6 million humanitarian contract is delivered and largely paid, and the Middle Eastern contract is de-risked by a letter of credit for the remaining deliveries.
• Balance sheet strengthening: Net debt down to £6.7 million and expected to fall further gives the Group more options and resilience.

What could temper the enthusiasm

• Contract concentration: Big contracts can be lumpy. It’s not yet clear how much of the H1 step-up was one-off versus repeatable run-rate demand. No order book value is disclosed.
• Margin details missing: We know margins improved, but not by how much. The durability of margin gains will be a key watch-out at interims.
• Execution milestones: A small portion of humanitarian cash is tied to installation, and Middle East deliveries hinge on finalising a letter of credit. Both are progressing, but timing matters for H2 cash flow.

Jargon buster in 30 seconds

• Gross margin: The profit after manufacturing and distribution costs, before overheads. Higher is better.
• Capital items: Big-ticket equipment like ventilators, typically higher margin than consumables.
• EBITDA: Earnings before interest, tax, depreciation and amortisation – a proxy for operating cash profit. The Company says it improved, but didn’t disclose a figure.
• Letter of credit: A bank guarantee that the seller will be paid on delivery – commonly used in international trade.

What to ask on 7 October: the investor checklist

• How much of the 41% growth came from capital equipment versus consumables and distributed products?
• What is the reported gross margin percentage and how does it compare to last year?
• Interim EBITDA and operating cash flow – how strong was cash conversion in H1?
• Order book visibility and the expected cadence of shipments for H2 FY26.
• Status and timing for the remaining humanitarian installation payments and the Middle Eastern letter of credit.
• Any changes to full-year expectations and priorities for cash – further debt reduction, investment, or both?

My take: promising momentum, with the right kind of improvements

This is a clean, confidence-building update. Record revenue, better margins and lower net debt are exactly what shareholders wanted to see from a turnaround that focuses on core neonatal technology and disciplined execution. The conversion of large contracts into delivered and paid revenue is a tangible proof point.

The remaining caution is around sustainability. We need to see how much of H1’s strength came from one-off contracts and how much is repeatable run-rate business. Clarity on margins and cash flow on 7 October will be key. For now, though, the direction of travel is firmly positive and the balance sheet is moving the right way.